Number of pages: 100 | Report Format: PDF | Published date: July 05, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
Report Attribute |
Details |
CAGR |
13.2% |
Base Year for Estimation |
2022 |
Forecast Period |
2023 to 2031 |
Historical Year |
2021 |
Segments Covered |
Indication, Distribution Channel, and Region |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the subcutaneous immunoglobulin (SCIg) therapy market is expected to register a revenue CAGR of 13.2% during the forecast period.
Subcutaneous Immunoglobulin (SCIg) Therapy Market Fundamentals
Subcutaneous immunoglobulin (SCIg) therapy is a form of immunoglobulin replacement therapy delivered via subcutaneous injection. It treats primary immunodeficiency disorders and conditions characterized by impaired immune function. SCIg therapy has gained significant traction in recent years due to its convenience, patient-friendly administration, and comparable efficacy to intravenous immunoglobulin (IVIg) therapy.
Immunoglobulin (Ig) replacement has long been used to treat a wide variety of primary and secondary antibody deficiencies and autoimmune disorders. In 1980, the United States had 1st launched slow subcutaneous immunoglobulin (SCIg) infusions utilizing portable syringe drivers. Subsequently, portions of Europe and New Zealand adopted the practice. Even though slow subcutaneous infusions were an advancement over intramuscular infusions, they took a long time and had a relatively small volume that could be given at a time. The SCIg did not become renowned at that time as a result. Since intravenous immunoglobulin (IVIg) formulations were readily available in the early 1980s, nearly all primary immunodeficiency (PID) patients in the United States have been treated intravenously.
Subcutaneous immunoglobulin (SCIg) delivery has grown in popularity in recent years. The technique has been shown to improve patients' quality of life and does not require venous access. It also has little systemic negative effects. The use of subcutaneous immunoglobulin (SCIg) in patients who had previously received the intravenous formulation has been the subject of most research undertaken so far. The use of SCIg administration in individuals with primary immunodeficiencies who had not previously received treatment is now supported by new evidence.
Subcutaneous Immunoglobulin (SCIg) Therapy Market Dynamics
The growing prevalence of immunodeficiency disorders drives the global subcutaneous immunoglobulin (SCIg) therapy market revenue. The increasing prevalence of primary immunodeficiency disorders, such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA), is a major driver for the SCIg therapy market. The growing awareness and diagnosis of these conditions contribute to the demand for SCIg therapy. Additionally, SCIg therapy offers the advantage of home administration, allowing patients to self-administer or receive treatment from caregivers in a familiar environment. This shift towards home-based treatment contributes to the market revenue growth, as it enhances patient convenience and reduces healthcare costs associated with hospital-based treatments.
Moreover, the advancements in infusion technology are propelling the market revenue share to a greater extent. The development of advanced infusion devices and technologies has improved the ease of administration and patient experience with SCIg therapy. Innovations such as wearable infusion pumps and automated injection devices have facilitated precise dosing and increased patient compliance. With the rising aging global population, there is a higher prevalence of immune-related disorders in the elderly. SCIg therapy is increasingly adopted in the geriatric population for conditions such as secondary immunodeficiency and autoimmune diseases, driving market revenue growth.
However, limited reimbursement coverage, high treatment costs, and lack of awareness are likely to restrain the market revenue growth. Despite the increasing acceptance of SCIg therapy, reimbursement coverage for home-based infusion therapies vary across regions. Inadequate reimbursement policies and complex reimbursement procedures can hinder market growth and patient access to SCIg therapy. Furthermore, the cost of SCIg therapy is relatively higher compared to traditional IVIg therapy. The expenses associated with the frequent administration of SCIg therapy, including the cost of infusion devices and supplies, can pose financial challenges for patients and limit market revenue growth.
Additionally, many healthcare professionals and patients may still be unfamiliar with SCIg therapy or have limited knowledge of its benefits and administration. Rising awareness, providing education, and enhancing training programs for healthcare providers is crucial for increasing the adoption of SCIg therapy. This overall restrain the market revenue growth.
Subcutaneous Immunoglobulin (SCIg) Therapy Market Ecosystem
The global phenylpiperidine derivatives market is analyzed from three perspectives: indication, distribution channel, and region.
Subcutaneous Immunoglobulin (SCIg) Therapy Market by Indication
Based on indication, the global subcutaneous immunoglobulin (SCIg) therapy market is segmented into primary immunodeficiency disease (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), and others [Idiopathic Thrombocytopenic Purpura (ITP), multifocal motor neuropathy (MMN), etc.].
During the forecast period, the primary immunodeficiency disease segment is expected to account for the largest revenue share. The increasing frequency of primary immunodeficiency diseases, increased subcutaneous immunoglobulin usage and awareness, and increasing research and development efforts in the area of plasma-derived therapies are all factors contributing to the segment's dominance in terms of revenue share. For instance, in 2017, the International Union of Immunological Societies (IUIS) classification included 354 primary immunodeficiency diseases with 344 underlying genetic disorders; the 2019 classification has 404 primary immunodeficiency diseases with 430 underlying genetic disorders. Numerous primary immunodeficiency diseases are strongly associated with ethnicity and location, and certain PIDs, such as Mendelian susceptibility to mycobacterial illnesses (MSMD), are more prevalent in the Indian population. Another instance is that according to the Immune Deficiency Foundation, approximately 250,000 Americans have been diagnosed with primary immunodeficiency diseases. The prevalence of severe mixed immunodeficiency disease decreased from 1 in 10,000 in 2008 to 1 in 4000 in 2019. Primary immunodeficiency diseases are becoming more common, further driving market growth.
Subcutaneous Immunoglobulin (SCIg) Therapy Market by Distributional Channel
Based on the distributional channel, the global subcutaneous immunoglobulin (SCIg) Therapy Market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacy dominates the global subcutaneous immunoglobulin market with a high revenue share and is likely to rise with a sizable revenue share during the forecast period. This huge income share might be attributed to many patients visiting the hospital for the necessary diagnosis and treatment and purchasing most drugs from the hospitals. Hospital pharmacies play a significant role in the distribution of SCIg therapy. They are responsible for dispensing the therapy to patients receiving treatment in hospital settings. Hospital pharmacies ensure the availability of SCIg products and provide support and guidance to healthcare professionals and patients. Furthermore, they are available in rural or low-income communities, allowing patients to receive medications in these places.
The retail pharmacy segment accounted for the second-largest revenue share in 2022. Because there are more retail pharmacies in developed countries, there are chances of increasing market revenue. Some important factors fostering the market's revenue growth include affordability, convenience, and the straightforward availability of therapeutic medications at the preferred location. Due to its accessibility, patients also fill their prescriptions in retail pharmacies. Additionally, pharmacists can offer detailed instructions about dose and administration. Retail pharmacies, including chain and independent pharmacies, can serve as distribution points for SCIg therapy. They provide convenience and accessibility to patients who prefer to pick up their medication locally. Retail pharmacies may also offer counseling and guidance on SCIg therapy administration.
Subcutaneous Immunoglobulin (SCIg) Therapy Market by Region
Based on region, The subcutaneous immunoglobulin (SCIg) therapy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America is expected to lead the subcutaneous immunoglobulin market throughout the forecast period with the largest revenue share. The presence of major players, the high prevalence of patients with primary immunodeficiency diseases, the rising geriatric population in the area, and the region's well-established healthcare infrastructure are some of the main factors responsible for the market's revenue growth. In addition, encouraging government efforts and a rise in research collaboration numbers are among the factors expected to boost market revenue expansion.
The market for subcutaneous immunoglobulin in Asia Pacific is the fastest-growing region regarding revenue share and is expected to grow swiftly during the forecast period. The expected revenue CAGR for Asia Pacific in the subcutaneous immunoglobulin (SCIg) therapy market is 14%. The World Health Organization estimates that the number of elderly people worldwide will increase from 900 million in 2015 to around 2 billion (22% of the world's population) by 2050. The fastest-growing senior populations are anticipated in the near future in nations like South Korea, India, China, Thailand, and China. Factors such as increasing healthcare expenditure, rising prevalence of immunodeficiency disorders, and improving healthcare infrastructure contribute to the market expansion in this region.
Europe has a prominent market for SCIg therapy, with countries such as Germany, France, and the United Kingdom leading in terms of market size and adoption. The presence of advanced healthcare systems, favorable reimbursement policies, and a strong focus on patient-centered care contribute to the growth of the SCIg therapy market in Europe.
Competitive Landscape of Subcutaneous Immunoglobulin (SCIg) Therapy Market
The following companies are major participants in the global subcutaneous immunoglobulin (SCIg) market:
Strategic Developments in Subcutaneous Immunoglobulin (SCIg) Therapy Market
Subcutaneous Immunoglobulin (SCIg) therapy is a form of immunoglobulin replacement therapy delivered via subcutaneous injection. It treats primary immunodeficiency disorders and other conditions characterized by impaired immune function.
The subcutaneous immunoglobulin (SCIg) therapy market is expected to register a revenue CAGR of 13.2% during the forecast period.
Octapharma AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Kedrion S.p.A, and Grifols are among the prominent players operating in the global subcutaneous immunoglobulin (SCIg) therapy market.
High treatment costs, limited reimbursement policies, and a lack of awareness among the population are expected to restrain market revenue growth.
The market for subcutaneous immunoglobulin in Asia Pacific is the fastest-growing region in terms of revenue share. It is expected to grow swiftly during the forecast period due to large healthcare expenditures, rising prevalence of immunodeficiency disorders, and improving healthcare infrastructure.
*Insights on financial performance are subject to the availability of information in the public domain